[{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Monomethyl Auristatin E","moa":"synthetic analogs of the dolastatin series","graph1":"Oncology","graph2":"Phase I","graph3":"MBrace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MBrace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MBrace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"MBRC-101","moa":"EphA5 MMAE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MBrace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MBrace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MBrace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"TPG Life Sciences Innovations","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Series B Financing","leadProduct":"Monomethyl Auristatin E","moa":"synthetic analogs of the dolastatin series","graph1":"Oncology","graph2":"Phase I","graph3":"MBrace Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"MBrace Therapeutics \/ TPG Life Sciences Innovations","highestDevelopmentStatusID":"6","companyTruncated":"MBrace Therapeutics \/ TPG Life Sciences Innovations"},{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"MBRC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MBrace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MBrace Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MBrace Therapeutics \/ Undisclosed"}]